Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Angitia Incorporated Limited
This Phase 1 ethnobriding study will evaluate the pharmacokinetics, pharmacodynamics, and safety of AGA2118 in Japanese, Chinese, and Caucasian participants. Participants will be administered AGA2118 at the start of the study and followed for 85 days.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy males or females, aged 18 to 65 years
25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study
Meet the criteria for Japanese, Chinese, or Caucasian ethnicity
You may not be if
Participating or have participated in another clinical trial within the past 6 months
Any bone fracture within the past 6 months
History of myocardial infarction or stroke within the past 12 months
Malignancy within the past 5 years
Current hyper- or hypocalcemia
Pregnant or breastfeeding women, or women planning to become pregnant during the study
